KDR and neoplasm: The REGONIVO, REGOTORI, and REGOMUN studies demonstrated that VEGF/VEGFR inhibition can normalize tumor vasculature, improve oxygenation, and synergize with immunotherapy by enhancing T-cell priming and activation [12,13,14].